Seminars in Oncology
Volume 32, Issue 3 , Pages 315-328 , June 2005

Current Management of Advanced Non-Small Cell Lung Cancer: Targeted Therapy

  • Takeshi Isobe
    • ,
  • Roy S. Herbst
    • ,
  • Amir Onn

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Amir Onn, MD, Department of Pulmonary Medicine, Unit 403, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030

References 

  1. Jemal A , Murray T, Ward E , et al.   Cancer statistics, 2005 . CA Cancer J Clin . 2005;55:10–30
  2. Bunn PA . Chemotherapy for advanced non-small-cell lung cancer (Who, what, when, why?) . J Clin Oncol . 2002;20(suppl 18):23s–33s
  3. Mendelsohn J . Targeting the epidermal growth factor receptor for cancer therapy . J Clin Oncol . 2002;20(suppl 18):1s–13s
  4. Grünwald V , Hidalgo M . Developing inhibitors of the epidermal growth factor receptor for cancer treatment . J Natl Cancer Inst . 2003;95:851–867
  5. Kerbel R , Folkman J . Clinical translation of angiogenesis inhibitors . Nat Rev Cancer . 2002;2:727–739
  6. Ruoslahti E . Specialization of tumour vasculature . Nat Cancer Rev . 2002;2:83–90
  7. Schlessinger J . Cell signaling by receptor tyrosine kinases . Cell . 2000;103:211–225
  8. Olayioye MA , Neve RM , Lane HA . The ErbB signaling network (Receptor heterodimerization in development and cancer) . EMBO J . 2000;19:3159–3167
  9. Dazzi H , Hasleton PS , Thatcher N , et al.   Expression of epidermal growth factor receptor (EGF-R) in non-small cell lung cancer. Use of archival tissue and correlation of EGF-R with histology, tumour size, node status and survival . Br J Cancer . 1989;59:746–749
  10. Tateishi M , Ishida T , Kohdono S , et al.   Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma . Surg Oncol . 1994;3:109–113
  11. Pastorino U , Andreola S , Tagliabue E , et al.   Immunocytochemical markers in stage I lung cancer (Relevance to prognosis) . J Clin Oncol . 1997;15:2858–2865
  12. Rusch V , Klimstra D , Venkatraman E , et al.   Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression . Clin Cancer Res . 1997;3:515–522
  13. Greatens TM , Niehans GA , Rubins JB , et al.   Do molecular markers predict survival in non-small-cell lung cancer? . Am J Respir Crit Care Med . 1998;157:1093–1097
  14. Pfeiffer P , Nexo E , Bentzen SM , et al.   Enzyme-linked immunosorbent assay of epidermal growth factor receptor in lung cancer (Comparisons with immunohistochemistry, clinicopathological features and prognosis) . Br J Cancer . 1998;78:96–99
  15. Volm M , Rittgen W , Drings P . Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas . Br J Cancer . 1998;77:663–669
  16. Fontanini G , De Laurentiis M , Vignati S , et al.   Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer (Amphiregulin and microvessel count are independent prognostic indicators of survival) . Clin Cancer Res . 1998;4:241–249
  17. Fu XL , Zhu XZ , Shi DR , et al.   Study of prognostic predictors for non-small cell lung cancer . Lung Cancer . 1999;23:143–152
  18. D’Amico TA , Massey M , Herndon JE , et al.   A biologic risk model for stage I lung cancer (Immunohistochemical analysis of 408 patients with the use of ten molecular markers) . J Thorac Cardiovasc Surg . 1999;117:736–743
  19. Ohsaki Y , Tanno S , Fujita Y , et al.   Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression . Oncol Rep . 2000;7:603–607
  20. Cox G , Jones JL , O’Byrne KJ . Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer . Clin Cancer Res . 2000;6:2349–2355
  21. Lai WW , Chen FF , Wu MH , et al.   Immunohistochemical analysis of epidermal growth factor receptor family members in stage I non-small cell lung cancer . Ann Thorac Surg . 2001;72:1868–1876
  22. Kanematsu T , Yano S , Uehara H , et al.   Phosphorylation, but not overexpression, of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients . Oncol Res . 2003;13:289–298
  23. Hirsch FR , Varella-Garcia M , Bunn PA , et al.   Epidermal growth factor receptor in non-small-cell lung carcinomas (Correlation between gene copy number and protein expression and impact on prognosis) . J Clin Oncol . 2003;21:3798–3807
  24. Onn A , Correa AM , Gilcrease M , et al.   Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer . Clin Cancer Res . 2004;10:136–143
  25. Reissmann PT , Koga H , Figlin RA , et al.   Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer . J Cancer Res Clin Oncol . 1999;125:61–70
  26. Meert AP , Martin B , Delmotte P , et al.   The role of EGF-R expression on patient survival in lung cancer (A systematic review with meta-analysis) . Eur Respir J . 2002;20:975–981
  27. Pedersen MW , Meltorn M , Damstrup L , et al.   The type III epidermal growth factor receptor mutation . Ann Oncol . 2001;12:745–760
  28. Lynch TJ , Bell DW , Sordella R , et al.   Activating mutations in the epidermal growth factor receptor underlying responsiveness fo non-small-cell lung cancer to gefitinib . N Engl J Med . 2004;350:2129–2139
  29. Paez JG , Janne PA , Lee JC , et al.   EGFR mutations in lung cancer (Correlation with clinical response to gefitinib therapy) . Science . 2004;304:1497–1500
  30. Mendelsohn J , Baselga J . Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer . J Clin Oncol . 2003;21:2787–2799
  31. Herbst RS , Langer CJ . Epidermal growth factor receptors as a target for cancer treatment (The emerging role of IMC-C225 in the treatment of lung and head and neck cancers) . Semin Oncol . 2002;29:27–36
  32. Robert F , Blumenschein G , Dicke K , et al.   Phase IB/IIIA study of anti-epidermal growth factor receptor antibody, cetuximab, in combination with gemcitabine/carboplatin in patients with advanced stage IV non-small cell lung cancer . Proc Am Soc Clin Oncol . 2003;22:643; (abstr)
  33. Kelly K , Hanna N , Rosenberg A , et al.   A multicenter phase I/II study of anti-epidermal growth factor receptor antibody, cetuximab, in combination with paclitaxel and carboplatin in patients with IV non-small cell lung cancer . Proc Am Soc Clin Oncol . 2003;22:644; (abstr)
  34. Kim E , Mauer A , Tran H , et al.   A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer (Final report) . Proc Am Soc Clin Oncol . 2003;22:642; (abstr)
  35. Gatzemeier U , Rosell R , Ramlau R , et al.   Cetuximab (Erbitux) in combination with cisplatin/vinorelbine vs cisplatin/vinorelbine alone in the first-line treatment of patients with epidermal growth factor receptor-expressing advanced non-small cell lung cancer . Proc Am Soc Clin Oncol . 2003;22:642; (abstr)
  36. Rosell R , Daniel C , Ramlau R , et al.   Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC) . Proc Am Soc Clin Oncol . 2004;23:618a
  37. Herbst RS , Kies MS . ZD1839 (Iressa) in non-small cell lung cancer . Oncologist . 2002;7(suppl 4):9–15
  38. Herbst RS . Erlotinib (Tarceva) (An update on the clinical trial program) . Semin Oncol . 2003;30(suppl 7):34–46
  39. Fukuoka M , Yano S , Giaccone G , et al.   Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer . J Clin Oncol . 2003;21:2237–2246
  40. Kris MG , Natale RB , Herbst RS , et al.   Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer (A randomized trial) . JAMA . 2003;290:2149–2158
  41. Dancey JE , Freidlin B . Targeting epidermal growth factor receptor—Are we missing the mark? . Lancet . 2003;362:62–64
  42. Giaccone G , Herbst RS , Manegold C , et al.   Gefitinib (ZD1839) in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer (A phase III trial (INTACT 1)) . J Clin Oncol . 2004;22:777–784
  43. Herbst RS , Giaccone G , Schiller JH , et al.   Gefitinib (ZD1839) in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer (A phase III trial (INTACT 2)) . J Clin Oncol . 2004;22:785–794
  44. Gatzemeier U , Pluzanska A , Szczesna A , et al.   Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer . Proc Am Soc Clin Oncol . 2004;22:7010
  45. Herbst RS , Drager D , Herman R , et al.   TRIBUTE—A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer . Proc Am Soc Clin Oncol . 2004;22:7011
  46. Shepherd FA , Pereira J , Ciuleanu TE , et al.   A randomized placebo-controlled trial of erlotinib in patients with non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial . J Clin Oncol . 2004;22:145
  47. Pao W , Miller VA . Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer (Current knowledge and future directions) . J Clin Oncol . 2005;23:2268–2556
  48. Shigematsu H , et al.   Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers . J Natl Cancer Inst . 2005;97:339–346
  49. Pegram M , Hsu S , Lewis G , et al.   Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers . Oncogene . 1999;18:2241–2251
  50. Schiller J , Langer CJ , Thor A , et al.   Trastuzumab in combination with paclitaxel/carboplatin advanced non-small cell lung cancer (Final report of ECOG 2598) . Proc Am Soc Clin Oncol . 2003;22:648; (abstr)
  51. Gatzemeier U , Groth G , Butts C , et al.   Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer . Ann Oncol . 2004;15:19–27
  52. Zinner RG , Kim J , Herbst RS . Non-small cell lung cancer clinical trials with trastuzumab (their foundation and preliminary results) . Lung Cancer . 2002;37:17–27
  53. Huncharek M , Muscat J , Geschwind JF . K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer (A combined analysis of 881 cases) . Carcinogenesis . 1999;20:1507–1510
  54. Downward J . Ras signaling and apoptosis . Curr Opin Genet Dev . 1998;8:9–54
  55. Adjei AA . An overview of farnesyltransferase inhibitors and their role in lung cancer therapy . Lung Cancer . 2003;41:55–62
  56. Web page accessed 2/5/04: http://www.schering-plough.com/schering-plough/news/release.jsp?releaseID=492402
  57. Hidalgo M , Eckhardt SG . Development of matrix metalloproteinase inhibitors in cancer therapy . J Natl Cancer Inst . 2001;93:178–193
  58. Laack E , Kohler A , Kugler C , et al.   Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer . Ann Oncol . 2002;13:1550–1557
  59. Smylie M , Mercier R , Aboulafia D , et al.   Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat in patients having advanced non-small cell lung cancer . Proc Am Soc Clin Oncol . 2001;20:307; (abstr)
  60. Bissett D , Pawel J , Mercier R , et al.   Phase III study of the matrix metalloprotease inhibitor prinomastat in combination with gemcitabine and cisplatin in non-small cell lung cancer . Proc Am Soc Clin Oncol . 2002;21:296; (abstr)
  61. Franqois B , Champagne P , Evans W , et al.   Phase I/II trials on the safety, tolerability and efficacy of Æ-941 (Neovastat) in patients with solid tumors . Proc Am Soc Clin Oncol . 2001;20:277; (abstr)
  62. Leighl NB , Shepherd F , Pazares L , et al.   Randomized phase II-III study of matrix metalloproteinase inhibitor (MMPI) BMS-275291 in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC) (NCIC-CTG BR.18) . J Clin Oncol . 2004;22(suppl): (abstr)
  63. Swannie HC , Kaye SB . Protein kinase C inhibitors . Curr Oncol Rep . 2002;4:37–46
  64. Yuen A , Advani R , Fisher G , et al.   Phase I/II trial of ISIS 3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in non-small cell lung cancer . Proc Am Soc Clin Oncol . 2001;19:167; (abstr)
  65. Ritch P , Belt R , George S , et al.   Phase I/II trial of ISIS 3521/LY900003, an antisense inhibitor of PKC-alpha with cisplatin and gemcitabine in advanced non-small cell lung cancer . Proc Am Soc Clin Oncol . 2002;21:1233; (abstr)
  66. Lynch TJ , Raju R , Lind M , et al.   A. Randomized phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC: Initial report . Proc Am Soc Clin Oncol . 2003;22:623; (abstr)
  67. Chambon P . The retinoid signaling pathway (molecular and genetic analyses) . Semin Cell Biol . 1994;5:115–125
  68. Lippman SM , Lee JJ , Karp DD , et al.   Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer . J Natl Cancer Inst . 2001;93:605–618
  69. Khuri FR , Rigas JR , Figlin RA , et al.   Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer . J Clin Oncol . 2001;19:2626–2637
  70. Folkman J . Tumor angiogenesis (Therapeutic implications) . N Engl J Med . 1971;285:1182–1186
  71. Bergers G , Benjamin LE . Tumorigenesis and the angiogenic switch . Nat Rev . 2003;3:401–410
  72. Folkman J . Angiogenesis in cancer, vascular, rheumatoid and other disease . Nat Med . 1995;1:27–31
  73. Senger DR , Perruzzi CA , Feder J . A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines . Cancer Res . 1986;46:5629–5632
  74. Ohta Y , Endo Y , Tanaka M , et al.   Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer . Clin Cancer Res . 1996;2:1411–1416
  75. Volm M , Koomagi R , Mattern J , et al.   Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer . Int J Cancer . 1997;74:64–68
  76. Imoto H , Osaki T , Taga S , et al.   Vascular endothelial growth factor expression in non-small-cell lung cancer (Prognostic significance in squamous cell carcinoma) . J Thorac Cardiovasc Surg . 1998;115:1007–1014
  77. Shibusa T , Shijubo N , Abe S . Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma . Clin Cancer Res . 1998;4:1483–1487
  78. Giatromanolaki A , Koukourakis MI , Kakolyris S , et al.   Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer . Clin Cancer Res . 1998;4:3017–3024
  79. Fontanini G , Boldrini L , Vignati S , et al.   Bcl2 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lung carcinoma . Eur J Cancer . 1998;34:718–723
  80. Aikawa H , Takahashi H , Fujimura S , et al.   Immunohistochemical study on tumor angiogenic factors in non-small cell lung cancer . Anticancer Res . 1999;19:4305–4309
  81. Volm M , Koomagi R , Mattern J . PD-ECGF, bFGF, and VEGF expression in non-small cell lung carcinomas and their association with lymph node metastasis . Anticancer Res . 1999;19:651–655
  82. Ohta Y , Tomita Y , Oda M , et al.   Tumor angiogenesis and recurrence in stage I non-small cell lung cancer . Ann Thorac Surg . 1999;68:1034–1038
  83. Shijubo N , Uede T , Kon S , et al.   Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma . Am J Respir Crit Care Med . 1999;160:1269–1273
  84. Yano T , Tanikawa S , Fujie T , et al.   Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer . Eur J Cancer . 2000;36:601–609
  85. Masuya D , Huang C , Liu D , et al.   The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in non-small cell lung carcinoma patients . Cancer . 2001;92:2628–2638
  86. Toomey D , Smyth G , Condron C , et al.   Immune function, telomerase, and angiogenesis in patients with primary, operable non-small cell lung carcinoma (Tumor size and lymph node status remain the most important prognostic features) . Cancer . 2001;92:2648–2657
  87. Baillie R , Carlile J , Pendleton N , et al.   Prognostic value of vascularity and vascular endothelial growth factor expression in non-small cell lung cancer . J Clin Pathol . 2001;54:116–120
  88. Han H , Silverman JF , Santucci TS , et al.   Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis . Ann Surg Oncol . 2001;8:72–79
  89. Minami K , Saito Y , Imamura H , et al.   Prognostic significance of p53, Ki-67, VEGF and Glut-1 in resected stage I adenocarcinoma of the lung . Lung Cancer . 2002;38:51–57
  90. Ferrara N , Gerber HP , LeCouter J . The biology of VEGF and its receptors . Nature Med . 2003;9:669–676
  91. Stacker SA , Achen MG , Jussila L , et al.   Lymphangiogenesis and cancer metastasis . Nat Rev Cancer . 2002;2:573–583
  92. Scappaticci FA . Mechanisms and future directions for angiogenesis-based cancer therapies . J Clin Oncol . 2002;20:3906–3927
  93. Kim ES , Herbst RS . Angiogenesis inhibitors in lung cancer . Curr Oncol Rep . 2002;4:325–333
  94. Herbst RS , Hidalgo M , Pierson AS , et al.   Angiogenesis inhibitors in clinical development for lung cancer . Semin Oncol . 2002;29(suppl 4):66–77
  95. Presta LG , Chen H , O’Connor SJ , et al.   Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders . Cancer Res . 1997;57:4593–4599
  96. Margolin K , Gordon MS , Holmgren E , et al.   Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer (Pharmacologic and long-term safety data) . J Clin Oncol . 2001;19:851–856
  97. Gordon MS , Margolin K , Talpaz M , et al.   Phase I safety and pharmachokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer . J Clin Oncol . 2001;19:843–850
  98. Johnson DH , Fehrenbacher L , Novotny WF , et al.   Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced metastatic non-small-cell lung cancer . J Clin Oncol . 2004;22:2184–2191
  99. Hurwitz H , Fehrenbacher L , Novotny W , et al.   Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer . N Engl J Med . 2004;350:2335–2342
  100. Yang JC , Haworth L , Sherry RM , et al.   A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer . N Engl J Med . 2003;349:427–434
  101. Fong TA , Shawver LK , Sun L , et al.   SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types . Cancer Res . 1999;59:99–106
  102. Kuenen BC , Rosen L , Smit EF , et al.   Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors . J Clin Oncol . 2002;15:1657–1667
  103. Wu W , Isobe T , Itasaka S , et al.   ZD6474, a small molecule targeting VEGF and EGF receptor signaling, inhibits lung angiogenesis and metastasis and improves survival in an orthotopic model of non-small cell lung cancer . Proc Am Assoc Cancer Research . 2004;
  104. Hurwitz H , Holden SN , Eckhardt SG , et al.   Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling in patients with solid tumors . Proc Am Soc Clin Oncol . 2002;21:82; (abstr)
  105. Minami H , Ebi H , Tahara M , et al.   A phase I study of an oral VEGF receptor tyrosine kinase inhibitor ZD6474, in Japanese patients with solid tumors . Proc Am Soc Clin Oncol . 2003;21:194; (abstr)
  106. Davis PD , Dougherty GJ , Blakey DC , et al.   ZD6126 (A novel vascular-targeting agent that causes selective destruction of tumor vasculature) . Cancer Res . 2002;62:7247–7253
  107. Goto H , Yano S , Zhang H , et al.   Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice . Cancer Res . 2002;62:3711–3715
  108. Gadgeel SM , LoRusso PM , Wozniak AJ , et al.   A dose-escalation study of the novel vascular-targeting agent, ZD6126, in patients with solid tumors . Proc Am Soc Clin Oncol . 2002;21:110a; (abstr)
  109. O’Reilly MS , Boehm T , Shing Y , et al.   Endostatin (An endogenous inhibitor of angiogenesis and tumor growth) . Cell . 1997;88:277–285
  110. Herbst RS , Hess KR , Tran HT , et al.   Phase I study of recombinant human endostatin in patients with advanced solid tumors . J Clin Oncol . 2002;20:3792–3803
  111. Herbst RS , Johnson DH , Mininberg E , et al.   Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer . J Clin Oncol . 2005;23:2544–2555
  112. Steinbach G , Lynch PM , Phillips RK , et al.   The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis . N Engl J Med . 2000;342:1946–1952
  113. Hida T , Kozaki K , Muramatsu H , et al.   Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines . Clin Cancer Res . 2000;6:2006–2011
  114. Altorki N , Keresztes R , Port J . Celecoxib (Celebrex), a selective COX-2 inhibitor, enhances the response to preoperative paclitaxel/carboplatin in early stage non-small cell lung cancer . Proc Am Soc Clin Oncol . 2002;21:26; (abstr)
  115. Csiki I , Dang T , Gonzalez A , et al.   Cyclooxygenase-2 (COX-2) inhibition + docetaxel (Txt) in recurrent non-small cell lung cancer (NSCLC) (Preliminary results of a phase II trial (THO-0054)) . Proc Am Soc Clin Oncol . 2002;21:1187; (abstr)
  116. Liotta LA , Kohn EC . The microenvironment of the tumor-host interface . Nature . 2001;411:375–379
  117. Fidler IJ . The organ microenvironment and cancer metastasis . Differentiation . 2002;70:498–505
  118. Fox E , Curt GA , Balis FM . Clinical trial design for target-based therapy . Oncologist . 2002;7:401–409
  119. Goldman B . For investigational targeted drugs, combination trials pose challenges . J Natl Cancer Inst . 2003;95:1744–1746
  120. Baker CH , Kedar D , McCarty MF , et al.   Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas . Am J Pathol . 2002;161:929–938
  121. Brabender J , Danenberg KD , Metzger R , et al.   Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival . Clin Cancer Res . 2001;7:1850–1855
  122. Mininberg ED , Herbst RS , Henderson T , et al.   Phase I/II study of the recombinant humanized monoclonal anti-VEGF antibody bevacizumab and the EGFR-TK inhibitor erlotinib in patients with recurrent non-small cell lung cancer . Proc Am Soc Clin Oncol . 2003;22:627; (abstr)
  123. Onn A , Isobe T , Itasaka S , et al.   Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice . Clin Cancer Res . 2003;9:5532–5539

PII: S0093-7754(05)00086-2

doi: 10.1053/j.seminoncol.2005.02.016

Seminars in Oncology
Volume 32, Issue 3 , Pages 315-328 , June 2005

Article Tools

* Image Usage & Resolution